Rothwell Investment Advisors, LLC’s Atrium Therapeutics RNA Stock Holding History

Rothwell Investment Advisors, LLC’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17	Buy	+2	New	+$24	﹤0.01%	1127

Other funds holding RNA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Rothwell Investment Advisors, LLC's RNA Position: Q3 2026 in Review

Rothwell Investment Advisors, LLC opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 2 shares worth $17. The stake represents ﹤0.01% of the portfolio and ranks #1127 among its holdings.

33 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

Rothwell Investment Advisors, LLC held 2 shares of Atrium Therapeutics worth $17 as of Q3 2026.
Atrium Therapeutics was a new Rothwell Investment Advisors, LLC position in Q3 2026.
Atrium Therapeutics made up ﹤0.01% of Rothwell Investment Advisors, LLC's portfolio in Q3 2026, its #1127 holding.
33 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Rothwell Investment Advisors, LLC's 13F filing for Q3 2026, filed 6 Nov 2026.